Immediate Impact
8 standout
Citing Papers
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
Cancer immune evasion, immunoediting and intratumour heterogeneity
2025 Standout
Works of Miklós Egyed being referenced
Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.
2022
Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations
2014
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Miklós Egyed | 152 | 97 | 49 | 92 | 19 | 162 | |
| Tommaso Radice | 140 | 124 | 56 | 61 | 13 | 180 | |
| Jocelin Huang | 196 | 168 | 72 | 100 | 13 | 220 | |
| Olivier Mansier | 106 | 98 | 49 | 79 | 13 | 157 | |
| Rabia Shahswar | 118 | 152 | 40 | 67 | 12 | 179 | |
| Faye Feller | 95 | 121 | 24 | 105 | 25 | 179 | |
| Soo-Young Choi | 114 | 142 | 56 | 59 | 18 | 215 | |
| Giuseppe Auteri | 59 | 81 | 32 | 48 | 22 | 130 | |
| Christina Ganster | 44 | 60 | 21 | 59 | 17 | 140 | |
| Wanke Zhao | 86 | 91 | 36 | 87 | 14 | 174 | |
| Manjola Balliu | 122 | 101 | 32 | 142 | 15 | 225 |
All Works
Loading papers...